Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Genomic Vision SA (G09.MU)

Munich - Munich Delayed Price. Currency in EUR
0.07220.0000 (0.00%)
At close: 08:03AM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0722
Open0.0722
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's Range0.0722 - 0.0722
52 Week Range0.0722 - 0.3036
Volume100
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for G09.MU

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Genomic Vision’s cutting-edge TeloSizer® application to be used in cancer research

      GENOMICS | GENETICS | R&D | DIAGNOSIS TESTS Genomic Vision’s cutting-edge TeloSizer® application to be used in cancer research Genomic Vision and CNRS launch a core oncology program with the Cancer Research Center of Marseille to develop companion tests based on TeloSizer® Bagneux (France) – Genomic Vision (FR0011799907 – GV, the “Company”), a Euronext-listed biotechnology company that develops tools and services for the highly accurate characterization of DNA sequences, is pleased to announce a

    • Business Wire

      Genomic Vision and Cambridge Consultants, Part of Capgemini, Announce the Development of an Innovative Technology Platform for In-depth Genomic Analysis

      BAGNEUX, France & CAMBRIDGE, England, November 07, 2022--Regulatory News: Genomic Vision (FR0011799907 – GV, – the "Company") (Paris:GV), a Euronext-listed biotechnology company developing tools and services for the highly accurate characterization of DNA sequences, is pleased to announce the selection of Cambridge Consutants, a world-leading product development and technology consultancy, part of Capgemini Invent1, to jointly develop the next generation of a technology platform for the analysis

    • Business Wire

      Genomic Vision: Financial Information for the Third Quarter of 2022

      BAGNEUX, France, October 27, 2022--Regulatory News: Genomic Vision (FR0011799907 – GV, – the "Company") (Paris:GV), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announced its revenue and cash position for the nine-month ended on September 30, 2022.

    Advertisement
    Advertisement